The Cleveland Cardiometabolic Cohort

Sponsor
Grace McComsey (Other)
Overall Status
Recruiting
CT.gov ID
NCT03059121
Collaborator
(none)
60
1
71
0.8

Study Details

Study Description

Brief Summary

In this observational study, the investigators will examine the changes in body composition in HIV-infected subjects before and after initiation of HIV treatment, and look at the correlations with changes in cardiometabolic indices such as endothelial function and coronary calcium scoring.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Dual-energy X-ray absorptiometry

Detailed Description

The effects of lifestyle factors on body composition changes after antiretroviral therapy (ART) are unknown, and as such, investigators will use this prospective observational cohort to study relationships between lifestyle factors, including diet, physical activity and illicit drug use, with changes in body composition after ART. In addition, the effect of the body fat changes will be correlated to changes in cardiometabolic indices such as endothelial function and coronary calcium scoring.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observational Study of Cardiometabolic Risk in HIV Infected Subjects After Initiation of Antiretroviral Therapy: The Cleveland Cardiometabolic Cohort
Actual Study Start Date :
Sep 1, 2016
Anticipated Primary Completion Date :
Aug 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
HIV-infected ART-naïve

HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen

Diagnostic Test: Dual-energy X-ray absorptiometry

Outcome Measures

Primary Outcome Measures

  1. Body composition measures [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    Assessed using DEXA (dual energy x-ray absorptiometry) scans which will be quantifying total body fat

Secondary Outcome Measures

  1. Resting Energy Expenditure (REE) measures [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    Assessed using a BodyGem REE calculator (values in KCal)

  2. endothelial function measures [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    Assessed using EndoPAT (values reported as a reactive hyperemia index RHI)

  3. calcium score measures [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    Assessed using CT scans

  4. central obesity [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    measured with waist circumference using a tape measure (in cm)

  5. Lipids measures [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    used measuring blood levels of triglycerides (mg/dL); serum high-density lipoprotein (mg/dL) ; cholesterol (mg/dL); low density lipoprotein (mg/dL)

  6. Fasting plasma glucose measures [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    fasting plasma glucose test is performed after a person has fasted for at least 8 hours (measured in mg/dL)

  7. Metabolic syndrome [Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year]

    Metabolic syndrome will be defined using the following measures: central obesity, serum triglycerides , serum high-density lipoprotein (HDL); cholesterol levels and fasting plasma glucose

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test

  • Provides written informed consent and is capable of reading and comprehending the informed consent

  • Is not currently taking antiretroviral therapy and has never been on such treatments in the past. Exception would be for subjects who had been in the past on ≤30 days cumulative antiretrovirals, as long as these were stopped >6 months prior to study entry

  • Is planning on starting antiretroviral therapy as part of routine clinic care

Exclusion Criteria:
  • Pregnancy or lactation

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Case Medical Center Cleveland Ohio United States 44106

Sponsors and Collaborators

  • Grace McComsey

Investigators

  • Principal Investigator: Grace McComsey, MD, University Hospitals Cleveland Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Grace McComsey, Principle Investigator, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier:
NCT03059121
Other Study ID Numbers:
  • Pending
First Posted:
Feb 23, 2017
Last Update Posted:
Dec 16, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Grace McComsey, Principle Investigator, University Hospitals Cleveland Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 16, 2021